PharmChem, Inc. (PCHM)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PharmChem, Inc. (PCHM) with AI Score 49/100 (Weak). PharmChem, Inc. specializes in drug detection technology, offering the PharmChek Sweat Patch as an alternative to traditional urine testing. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026PharmChem, Inc. (PCHM) Healthcare & Pipeline Overview
PharmChem, Inc., based in Fort Worth, Texas, develops and provides the PharmChek Sweat Patch, an alternative drug testing method utilizing sweat for the detection of cocaine, opiates, amphetamines, PCP, and marijuana, positioning itself within the medical diagnostics sector.
Investment Thesis
PharmChem, Inc. presents a focused investment opportunity within the niche market of sweat-based drug detection. With a market capitalization of $0.02 billion and a P/E ratio of 18.80, the company demonstrates profitability, supported by a gross margin of 64.2% and a profit margin of 19.7%. The company's beta of 0.67 suggests lower volatility compared to the broader market. Growth catalysts include potential expansion into new geographic markets and increased adoption of sweat-based testing methodologies. However, the company faces risks associated with regulatory approvals, competition from established drug testing methods, and its small size. The absence of a dividend may deter some investors. The investment thesis hinges on PharmChem's ability to maintain its market share and capitalize on the growing demand for alternative drug testing solutions.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.02 billion indicates a micro-cap company with potential for high growth but also higher risk.
- P/E ratio of 18.80 suggests the company is trading at a reasonable valuation compared to its earnings.
- Profit margin of 19.7% demonstrates strong profitability and efficient operations.
- Gross margin of 64.2% indicates a significant competitive advantage in its niche market.
- Beta of 0.67 suggests lower volatility compared to the broader market, potentially offering a more stable investment.
Competitors & Peers
Strengths
- Proprietary PharmChek Sweat Patch technology
- Alternative to traditional urine testing
- Established presence in a niche market
- High gross margin of 64.2%
Weaknesses
- Small company size with only 9 employees
- Limited product line focused on a single product
- Reliance on a niche market with potential regulatory risks
- Lack of dividend may deter some investors
Catalysts
- Upcoming: Potential partnerships with substance abuse treatment centers to integrate PharmChek Sweat Patch into treatment programs.
- Upcoming: Expansion into new geographic markets, such as Europe and Asia, to increase revenue and market share.
- Ongoing: Increasing awareness of the benefits of sweat-based drug testing compared to traditional methods.
- Ongoing: Rising demand for alternative drug testing solutions in various sectors, including workplace and law enforcement.
- Upcoming: Development and launch of new sweat-based tests for other drugs of abuse and medical conditions.
Risks
- Potential: Regulatory changes affecting the acceptance and use of sweat-based drug testing.
- Potential: Competition from established drug testing methods and larger companies.
- Ongoing: Limited financial resources and small company size may hinder growth and expansion.
- Potential: Risk of product obsolescence due to technological advancements in drug testing.
- Ongoing: Dependence on a single product (PharmChek Sweat Patch) increases vulnerability to market changes.
Growth Opportunities
- Expansion into International Markets: PharmChem can explore opportunities to expand its market reach beyond the United States. The global drug testing market is expected to grow, driven by increasing awareness of drug abuse and stricter regulations in various countries. Entering new markets, such as Europe and Asia, could significantly increase PharmChem's revenue and market share. Timeline: 2-3 years.
- Partnerships with Substance Abuse Treatment Centers: Collaborating with substance abuse treatment centers can provide PharmChem with a steady stream of customers and enhance its brand recognition. By integrating the PharmChek Sweat Patch into treatment programs, PharmChem can demonstrate its effectiveness and reliability, leading to increased adoption. Timeline: 1-2 years.
- Development of New Sweat-Based Tests: PharmChem can invest in research and development to expand its portfolio of sweat-based tests. This could include tests for other drugs of abuse, as well as tests for medical conditions and biomarkers. By diversifying its product line, PharmChem can reduce its reliance on a single product and tap into new markets. Timeline: 3-5 years.
- Integration with Telehealth Platforms: As telehealth becomes increasingly prevalent, PharmChem can explore opportunities to integrate its sweat patch technology with telehealth platforms. This would allow healthcare providers to remotely monitor patients for drug use, improving adherence to treatment plans and reducing the risk of relapse. Timeline: 2-3 years.
- Focus on Workplace Drug Testing Programs: PharmChem can target companies and organizations that require drug testing for their employees. The PharmChek Sweat Patch offers a convenient and non-invasive alternative to urine testing, which may be more appealing to employees. By focusing on this market segment, PharmChem can secure long-term contracts and generate recurring revenue. Timeline: 1-2 years.
Opportunities
- Expansion into international markets
- Partnerships with substance abuse treatment centers
- Development of new sweat-based tests
- Integration with telehealth platforms
Threats
- Competition from established drug testing methods
- Regulatory changes affecting sweat-based testing
- Potential for product obsolescence due to technological advancements
- Economic downturn affecting demand for drug testing services
Competitive Advantages
- Proprietary sweat patch technology
- Alternative to traditional urine testing
- Established presence in the niche market of sweat-based drug detection
About PCHM
PharmChem, Inc., headquartered in Fort Worth, Texas, focuses on providing innovative drug detection solutions. The company's primary product is the PharmChek Sweat Patch, a non-invasive method for detecting the presence of drugs of abuse. Unlike traditional urine testing, the PharmChek Sweat Patch uses sweat as the sample source, offering a less intrusive and potentially more convenient option for drug screening. The patch is designed to detect cocaine, opiates, amphetamines, PCP, and marijuana. PharmChem's technology caters to various sectors, including substance abuse treatment programs, law enforcement, and workplace drug testing. The company aims to provide a reliable and accurate alternative to conventional drug testing methods, addressing the challenges associated with urine sample collection and potential adulteration. While the company's history and founding details are not available, its current focus remains on the production and distribution of the PharmChek Sweat Patch. PharmChem operates primarily within the United States, focusing on markets where sweat-based drug testing is accepted and utilized. The company's small size, with only 9 employees, suggests a niche market focus and a lean operational structure.
What They Do
- Provides PharmChek Sweat Patch for drug detection.
- Offers an alternative to urine testing.
- Detects cocaine, opiates, amphetamines, PCP, and marijuana.
- Uses sweat as the source for drug testing.
- Serves substance abuse treatment programs.
- Serves law enforcement agencies.
- Serves workplace drug testing programs.
Business Model
- PharmChem generates revenue through the sale of PharmChek Sweat Patches.
- The company targets substance abuse treatment centers, law enforcement, and employers.
- PharmChem focuses on providing a convenient and reliable alternative to traditional urine testing.
Industry Context
PharmChem, Inc. operates within the medical diagnostics and research industry, specifically focusing on drug testing solutions. The drug testing market is driven by factors such as increasing drug abuse rates, workplace safety regulations, and law enforcement needs. The industry includes various testing methods, including urine, blood, hair, and sweat analysis. PharmChem's PharmChek Sweat Patch competes with established urine testing methods and other alternative testing technologies. The company's success depends on its ability to differentiate its product through accuracy, convenience, and cost-effectiveness. The competitive landscape includes companies offering a range of drug testing products and services, requiring PharmChem to maintain a strong market position through innovation and strategic partnerships.
Key Customers
- Substance abuse treatment centers
- Law enforcement agencies
- Workplace drug testing programs
Financials
Chart & Info
PharmChem, Inc. (PCHM) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Dec 17, 2019
-
Stocks That Hit 52-Week Highs On Tuesday
· Sep 23, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PCHM.
Price Targets
Wall Street price target analysis for PCHM.
MoonshotScore
What does this score mean?
The MoonshotScore rates PCHM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thompson Clark CPA
CEO
Thompson Clark is a Certified Public Accountant (CPA) and serves as the CEO of PharmChem, Inc. With a background in accounting and finance, Clark brings financial expertise to the company's leadership. His experience likely includes financial management, strategic planning, and compliance. As the head of PharmChem, Clark is responsible for overseeing the company's operations, driving growth, and ensuring financial stability. He manages a small team of 9 employees.
Track Record: As CEO of PharmChem, Thompson Clark has overseen the company's operations in providing the PharmChek Sweat Patch for drug detection. His leadership has contributed to the company's profitability, as evidenced by its profit margin of 19.7%. Specific milestones and strategic decisions under his leadership are not available, but his role is crucial in guiding the company's growth and maintaining its market position.
PCHM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that PharmChem, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors and may be subject to greater risks. Trading on the OTC Other tier differs significantly from trading on major exchanges like the NYSE or NASDAQ, where companies must adhere to strict listing standards and reporting obligations. The OTC Other tier is often populated by shell companies, defunct companies, or companies with questionable financials.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in PCHM.
- Low liquidity can make it difficult to buy or sell shares.
- Potential for high price volatility due to low trading volume.
- Risk of delisting or trading suspension due to non-compliance with OTC regulations.
- Higher risk of fraud or manipulation compared to stocks listed on major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Check the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile for any warnings or disclosures.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Confirm the company's contact information and physical address.
- The company has been in operation for several years.
- PharmChem has a specific product (PharmChek Sweat Patch) with a defined application.
- The company has a CEO (Thompson Clark CPA) with a professional background.
- PharmChem has a small team of employees (9), suggesting a real operational presence.
- The company's product addresses a specific need in the drug testing market.
Common Questions About PCHM
What does PharmChem, Inc. do?
PharmChem, Inc. specializes in providing drug detection solutions, primarily through its PharmChek Sweat Patch. This patch offers an alternative to traditional urine testing by using sweat to detect the presence of drugs of abuse, including cocaine, opiates, amphetamines, PCP, and marijuana. The company caters to substance abuse treatment programs, law enforcement agencies, and workplace drug testing programs, providing a non-invasive and potentially more convenient method for drug screening. PharmChem aims to address the challenges associated with conventional drug testing methods by offering a reliable and accurate alternative.
What do analysts say about PCHM stock?
Currently, there is no available analyst coverage or consensus on PharmChem, Inc. (PCHM) stock. Given its micro-cap status and OTC listing, the company may not be actively tracked by major brokerage firms or research institutions. Investors should conduct their own thorough due diligence and consider the company's fundamentals, growth prospects, and risk factors before making any investment decisions. Key valuation metrics include its market capitalization of $0.02 billion, P/E ratio of 18.80, and profit margin of 19.7%.
What are the main risks for PCHM?
PharmChem, Inc. faces several risks inherent to its small size, OTC listing, and niche market focus. Regulatory changes affecting the acceptance of sweat-based drug testing could significantly impact its revenue. Competition from established drug testing methods and larger companies poses a threat to its market share. The company's limited financial resources may hinder its ability to invest in research and development or expand into new markets. Additionally, the dependence on a single product (PharmChek Sweat Patch) increases its vulnerability to market changes and technological advancements. The OTC listing also brings risks of low liquidity and potential price volatility.
What are the key factors to evaluate for PCHM?
PharmChem, Inc. (PCHM) currently holds an AI score of 49/100, indicating low score. Key strength: Proprietary PharmChek Sweat Patch technology. Primary risk to monitor: Potential: Regulatory changes affecting the acceptance and use of sweat-based drug testing.. This is not financial advice.
How frequently does PCHM data refresh on this page?
PCHM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PCHM's recent stock price performance?
Recent price movement in PharmChem, Inc. (PCHM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary PharmChek Sweat Patch technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PCHM overvalued or undervalued right now?
Determining whether PharmChem, Inc. (PCHM) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PCHM?
Before investing in PharmChem, Inc. (PCHM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Lack of analyst coverage for PCHM.
- Information based on available sources and may not be comprehensive.